|Bid||0.2000 x 0|
|Ask||0.2200 x 0|
|Day's Range||0.2000 - 0.2050|
|52 Week Range||0.1550 - 0.7950|
|Beta (3Y Monthly)||-1.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.27|
Brad O'Connor has been the CEO of Cogstate Limited (ASX:CGS) since 2005. This report will, first, examine the CEO...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It's not a secret that every investor will make bad investments, from time to time. But serious investors should think lo...
Cogstate Limited (ASX:CGS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CGS will Read More...
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that Pamela Ventola Phd, from Yale University has joined its Advisory Committee for its QBM-001 clinical program. QBM-001 is being developed and tested for the treatment of minimally verbal or non-verbal toddlers with an Autism Spectrum Disorder (ASD).
Brad O'Connor has been the CEO of Cogstate Limited (ASX:CGS) since 2005. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...
The cognitive science company, Cogstate Ltd (CGS.AX) today announced a presentation entitled, “Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research Approach” will be delivered at the National Organization for Rare Diseases (NORD) Rare Disease Summit in Washington, D.C. The poster will be presented on October 15, 2018 by co-author, Pam Ventola, Ph.D., who leads the Rare Disease and Pediatric Center of Excellence at Cogstate.
A look at the shareholders of Cogstate Limited (ASX:CGS) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see Read More...